Arno W. R. van Kuijk

Author

Also Known As

A W R van Kuijk, A. W. R. van Kuijk, A.W. Kuijk, A.W.R. van Kuijk, ARNO W.R. VAN KUIJK, Arno W R Van Kuijk, Arno W R van Kuijk, Arno W. R. van Kuijk, Arno W.R. van Kuijk, Marc R Kok

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

University of Amsterdam Amsterdam UMC Location University of Amsterdam Reade Amsterdam UMC Location Vrije Universiteit Amsterdam Radboud University Nijmegen

About

Arno W. R. van Kuijk is an author at University of Amsterdam specializing in dermatopathology, immunology, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	29
2	Immunology	1	1	29
3	Autoimmune Disease	1	1	29
4	Autoimmunity	1	1	29
5	Immunotherapy	1	1	29

Arno W. R. van Kuijk

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Endothelial Dysfunction Precedes Development of Microalbuminuria in IDDM Coen D.A. Stehouwer, H R Andreas Fischer, Arno W. R. van Kuijk, Diabetes	1995	211
Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment Arno W. R. van Kuijk, P Reinders-Blankert, Tom Smeets, Annals of the Rheumatic Diseases	2006	197
Alefacept treatment in psoriatic arthritis: Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis Maarten C. Kraan, Arno W. R. van Kuijk, Huibert J. Dinant, Arthritis & Rheumatism	2002	149
Patient Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA and OMERACT Study Alberto Cauli, Dafna D. Gladman, Alessandro Mathieu, The Journal of Rheumatology	2011	129
A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue Arno W. R. van Kuijk, Daniëlle M. Gerlag, Koen Vos, Annals of the Rheumatic Diseases	2008	95
Brief Report: A phase IIa, randomized, double‐blind, placebo‐controlled trial of apilimod mesylate, an interleukin‐12/interleukin‐23 inhibitor, in patients with rheumatoid arthritis Sarah Krausz, Maria J H Boumans, Daniëlle M. Gerlag, Arthritis & Rheumatism	2011	82
Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up Erik H Vogelzang, E. Kneepkens, Michael T. Nurmohamed, Annals of the Rheumatic Diseases	2014	79
CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial Arno W. R. van Kuijk, Clarissa E. Vergunst, Daniëlle M. Gerlag, Annals of the Rheumatic Diseases	2010	69
TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade Arno W. R. van Kuijk, Carla A. Wijbrandts, Marjolein Vinkenoog, Annals of the Rheumatic Diseases	2009	61
Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort Leonieke van Mens, M. G. H. Van de Sande, Arno W. R. van Kuijk, Annals of the Rheumatic Diseases	2017	58

Page 1